Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ZYME.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 -50.62M
March 31, 2026 178.79M
December 31, 2025 -18.78M
September 30, 2025 -2.496M
June 30, 2025 1.366M
March 31, 2025 1.316M
December 31, 2024 -8.258M
September 30, 2024 -14.91M
June 30, 2024 1.026M
March 31, 2024 2.129M
December 31, 2023 49.74M
September 30, 2023 1.924M
June 30, 2023 27.71M
March 31, 2023 1.738M
December 31, 2022 -2.907M
September 30, 2022 -0.8651M
June 30, 2022 -0.7155M
March 31, 2022 108.61M
December 31, 2021 0.678M
Date Value
September 30, 2021 4.469M
June 30, 2021 0.7141M
March 31, 2021 2.106M
December 31, 2020 7.627M
September 30, 2020 11.80M
June 30, 2020 -4.213M
March 31, 2020 302.83M
December 31, 2019 1.719M
September 30, 2019 3.050M
June 30, 2019 189.33M
March 31, 2019 0.569M
December 31, 2018 -0.4307M
September 30, 2018 -1.387M
June 30, 2018 91.42M
March 31, 2018 0.131M
December 31, 2017 -1.057M
September 30, 2017 2.464M
June 30, 2017 49.61M
March 31, 2017 -0.015M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Theravance Biopharma, Inc. -0.967M
BridgeBio Pharma, Inc. -148.77M
Aprea Therapeutics, Inc. -2.334M
ACADIA Pharmaceuticals, Inc. 10.49M
Alnylam Pharmaceuticals, Inc. 36.24M